Oncosil Medical Ltd
ASX:OSL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Arts Alliance SA
WSE:AAS
|
PL |
|
IReader Technology Co Ltd
SSE:603533
|
CN |
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
CA |
|
J.S. Corrugating Machinery Co Ltd
SZSE:000821
|
CN |
|
Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
|
CN |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Oncosil Medical Ltd
ASX:OSL
|
11.6m AUD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
961.5B USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
179.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
134.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
32.1B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
251.1B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.7B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
29.6B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Oncosil Medical Ltd
Glance View
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on unresectable locally advanced pancreatic cancer (LAPC). The firm's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. The company enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Oncosil Medical Ltd is -66.3%, which is above its 3-year median of -179.2%.
Over the last 3 years, Oncosil Medical Ltd’s Gross Margin has decreased from -61.2% to -66.3%. During this period, it reached a low of -427% on Dec 31, 2023 and a high of -61.2% on Dec 31, 2022.
